NEWRON PHARMACEUT. EO-20 Cash Flow Conversion Efficiency

Latest as of December 2025: 0.119x

NEWRON PHARMACEUT. EO-20 cash flow conversion efficiency. Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) has a cash flow conversion efficiency ratio of 0.119x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.33 Million ≈ $-1.55 Million USD) by net assets (€-11.13 Million ≈ $-13.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of NEWRON PHARMACEUT. EO-20 (2005–2025)

Cash flow conversion efficiency of NEWRON PHARMACEUT. EO-20 from 2005 to 2025. This chart illustrates how NEWRON PHARMACEUT. EO-20's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NEWRON PHARMACEUT. EO-20 (NP5) stock price for real-time trading data and today's change.

NEWRON PHARMACEUT. EO-20 Cash Flow Conversion Ratio Explained

NEWRON PHARMACEUT. EO-20 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

NEWRON PHARMACEUT. EO-20 Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NEWRON PHARMACEUT. EO-20 ranked by their cash flow conversion efficiency. Also see NEWRON PHARMACEUT. EO-20 (NP5) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Jiangsu Wanlin Modern Logistic SHG:603117	0.017x
Timbercreek Financial Corp TO:TF	0.011x
Tilray Inc TO:TLRY	-0.014x
Nanjing Chervon Auto Precision Technology Co Ltd SHG:603982	0.067x
Jiangsu Xinri E-Vehicle Co Ltd SHG:603787	0.161x
Armata Pharmaceuticals Inc NYSE MKT:ARMP	0.031x
NHN KCP Corp KQ:060250	0.513x
StealthGas Inc F:S6W	0.024x

Annual Cash Flow Conversion Efficiency for NEWRON PHARMACEUT. EO-20 (2005–2025)

The table below shows the annual cash flow conversion efficiency of NEWRON PHARMACEUT. EO-20 from 2005 to 2025. Review NEWRON PHARMACEUT. EO-20 free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€-11.13 Million ≈ $-13.01 Million	€32.56 Million ≈ $38.07 Million	-2.926x	+75.78%
2024-12-31	€1.46 Million ≈ $1.70 Million	€-17.61 Million ≈ $-20.59 Million	-12.081x	-3663.28%
2023-12-31	€-29.91 Million ≈ $-34.97 Million	€-10.14 Million ≈ $-11.85 Million	0.339x	-57.12%
2022-12-31	€-14.03 Million ≈ $-16.40 Million	€-11.09 Million ≈ $-12.97 Million	0.791x	+121.46%
2021-12-31	€3.11 Million ≈ $3.63 Million	€-11.45 Million ≈ $-13.38 Million	-3.684x	-307.54%
2020-12-31	€17.25 Million ≈ $20.16 Million	€-15.59 Million ≈ $-18.22 Million	-0.904x	-51.35%
2019-12-31	€36.80 Million ≈ $43.02 Million	€-21.98 Million ≈ $-25.69 Million	-0.597x	-105.27%
2018-12-31	€54.84 Million ≈ $64.11 Million	€-15.95 Million ≈ $-18.65 Million	-0.291x	-134.45%
2017-12-31	€67.72 Million ≈ $79.17 Million	€-8.40 Million ≈ $-9.83 Million	-0.124x	+68.48%
2016-12-31	€49.75 Million ≈ $58.16 Million	€-19.58 Million ≈ $-22.89 Million	-0.394x	-13.58%
2015-12-31	€37.11 Million ≈ $43.39 Million	€-12.86 Million ≈ $-15.04 Million	-0.347x	-1.43%
2014-12-31	€29.26 Million ≈ $34.21 Million	€-10.00 Million ≈ $-11.69 Million	-0.342x	+32.56%
2013-12-31	€21.09 Million ≈ $24.66 Million	€-10.69 Million ≈ $-12.49 Million	-0.507x	-340.15%
2012-12-31	€27.61 Million ≈ $32.28 Million	€5.83 Million ≈ $6.81 Million	0.211x	+128.11%
2011-12-31	€6.58 Million ≈ $7.70 Million	€-4.94 Million ≈ $-5.78 Million	-0.750x	+52.17%
2010-12-31	€12.19 Million ≈ $14.25 Million	€-19.13 Million ≈ $-22.36 Million	-1.569x	-99.27%
2009-12-31	€29.28 Million ≈ $34.23 Million	€-23.06 Million ≈ $-26.95 Million	-0.787x	-80.96%
2008-12-31	€45.81 Million ≈ $53.56 Million	€-19.93 Million ≈ $-23.30 Million	-0.435x	-80.11%
2007-12-31	€57.40 Million ≈ $67.11 Million	€-13.87 Million ≈ $-16.21 Million	-0.242x	-70.22%
2006-12-31	€67.86 Million ≈ $79.33 Million	€-9.63 Million ≈ $-11.26 Million	-0.142x	+83.14%
2005-12-31	€17.02 Million ≈ $19.90 Million	€-14.33 Million ≈ $-16.75 Million	-0.842x	--

About NEWRON PHARMACEUT. EO-20

XETRA:NP5 Germany Biotechnology

Market Cap

$306.87 Million

€262.49 Million EUR

Market Cap Rank

#14420 Global

#1455 in Germany

Share Price

€13.15

Change (1 day)

+0.77%

52-Week Range

€7.16 - €32.55

All Time High

€32.55